Skip to main content

Advertisement

SpringerLink
Log in

Bilateral subdural hemorrhage as a serious adverse event of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia

  • Letter to the Editor
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007;110:2309–15.

    Article  PubMed  CAS  Google Scholar 

  2. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531–41.

    Article  PubMed  CAS  Google Scholar 

  3. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109:5143–50.

    Article  PubMed  CAS  Google Scholar 

  4. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–70.

    Article  PubMed  CAS  Google Scholar 

  5. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658–61.

    Article  PubMed  CAS  Google Scholar 

  6. Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113:6322–9.

    Article  PubMed  CAS  Google Scholar 

  7. Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res. 2008;14:352–9.

    Article  PubMed  CAS  Google Scholar 

  8. Quintas-Cardama A, Kantarjian H, Ravandi F, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009;115:2482–90.

    Article  PubMed  CAS  Google Scholar 

  9. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997;277:242–5.

    Article  PubMed  CAS  Google Scholar 

  10. Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114:261–3.

    Article  PubMed  CAS  Google Scholar 

  11. Gratacap MP, Martin V, Valera MC, et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood. 2009;114:1884–92.

    Article  PubMed  CAS  Google Scholar 

  12. Christopher LJ, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008;36:1357–64.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (0620220-1).

Conflict of interest

The authors declare that there are no conflicts of interest.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Internal Medicine, Chonbuk National University Medical School, 20 Geonji-ro, Geumam-dong, Deokjin-gu, Jeonju, 561-712, Korea

    Ho-Young Yhim, Na-Ri Lee, Eun-Kee Song, Jae-Yong Kwak & Chang-Yeol Yim

  2. Department of Nursing, Woosuk University, Wanju, Korea

    Hee Sun Kim

  3. Advanced Research Cancer Center, Chonbuk National University Medical School, Jeonju, Korea

    Na-Ri Lee, Eun-Kee Song, Jae-Yong Kwak & Chang-Yeol Yim

Authors
  1. Ho-Young Yhim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hee Sun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Na-Ri Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eun-Kee Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jae-Yong Kwak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chang-Yeol Yim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jae-Yong Kwak.

About this article

Cite this article

Yhim, HY., Kim, H.S., Lee, NR. et al. Bilateral subdural hemorrhage as a serious adverse event of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol 95, 585–587 (2012). https://doi.org/10.1007/s12185-012-1045-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-012-1045-6

Keywords

Search

Navigation